Our Pipeline

Advancing new potential treatments for certain GI diseases affecting millions of patients in need

  • Product
  • Indication
  • PHASE I
  • PHASE II
  • PHASE III
  • Approval
  • Linzess® Partner

  • Launched 12/12

  • linaclotide Partner

  • IBS-C abdominal symptoms in adults (not an indication, additional data that may be added to the label)

    • Phase IIIb expected Mid-2019
  • linaclotide Partner

  • Functional constipation pediatrics

  • IW-3718

  • Persistent GERD

    • Phase III results expected 2H 2020
  • MD-7246 Partner

  • Abdominal pain associated with IBS with diarrhea (IBS-D)

    • Phase II trial expected to initiate 2Q 2019

Represents current phase of development, does not correspond to the initiation or completion of a particular phase.

Status of key development programs as of February 28, 2019.

Click here for LINZESS® full US Prescribing Information including BOXED WARNING.

Copyright © 2019, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.

You are now leaving www.IronwoodPharma.com.

This link will take you to a website to which our privacy policy does not apply. You are solely responsible for your interactions with that website.